STRO analyst estimates

Sutro Biopharma (STRO) analyst ratings, the average price target and its range, and every firm's latest call.

STRO analyst ratings and price targets

DateFirmCallTarget
Aug 7, 2026Stifel NicolausSutro Biopharma initiated with a Buy at Stifel$48.00
Jun 11, 2026Truist FinancialSutro Biopharma assumed with a Buy at Truist$50.00
May 28, 2026BarclaysBarclays Starts Sutro Biopharma (STRO) at Overweight$56.00
May 15, 2026Leerink PartnersSutro Biopharma price target raised to $43 from $38 at Leerink$43.00
May 15, 2026H.C. WainwrightSutro Biopharma price target raised to $50 from $28 at H.C. Wainwright$50.00
May 15, 2026WedbushSutro Biopharma upgraded to Outperform from Neutral at Wedbush$60.00
Apr 30, 2026Mizuho SecuritiesSutro Biopharma initiated with an Outperform at Mizuho$50.00
Mar 14, 2025Piper SandlerSutro Biopharma downgraded to Neutral from Overweight at Piper Sandler$2.00
Oct 11, 2024H.C. WainwrightH.C. Wainwright Reiterates Buy Rating on Sutro Biopharma (STRO)$12.00
Oct 11, 2024Bank of America SecuritiesBofA Securities Reiterates Buy Rating on Sutro Biopharma (STRO)$12.00
Aug 16, 2024Truist FinancialSutro Biopharma (STRO) PT Lowered to $15 at Truist Securities$15.00
May 14, 2024WedbushWedbush Reiterates Outperform Rating on Sutro Biopharma (STRO)$8.00
May 14, 2024Deutsche BankSutro Biopharma (STRO) PT Lowered to $10 at Deutsche Bank$10.00
Apr 3, 2024Piper SandlerSutro Biopharma (STRO) PT Lowered to $11 at Piper Sandler$11.00
Apr 3, 2024OppenheimerOppenheimer Reiterates Outperform Rating on Sutro Biopharma (STRO)$10.00